drugset / Trial / NCT04368585

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

NCT04368585

Phase 1 Completed 20 enrolled Spero Therapeutics
Non-randomizedCrossoverOpen-labelOther

Summary

To assess the effect of a single dose of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics (PK) of TBPM, following a single dose of TBPM-PI-HBr in healthy adult subjects.

Timeline

Start
2020-07-01
Primary completion
2020-08-08
Completion
2020-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Aluminum hydroxide Unknown 1600 mg Oral
Subject Omeprazole Other / unclassified 40 mg
Subject Simethicone Other / unclassified 1600 mg Oral
Subject TBPM-PI-HBr Small molecule 600 mg Oral
Subject magnesium hydroxide Unknown 1600 mg Oral

Indications

No indication recorded.